96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

- Farrell, Michael, Shahbazi, Jeyran, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa, Chambers, Mark, Byrne, Marianne, Gholami, Jaleh, Zahra, Emma, Grebely, Jason, Lintzeris, Nicholas, Larance, Briony, Ali, Robert

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence

- Farrell, Michael, Shahbazi, Jeyran, Byrne, Marianne, Grebely, Jason, Lintzeris, Nicholas, Chambers, Mark, Larance, Briony, Ali, Robert, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Nicholas, Thomas, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1

- Shahbazi, Jeyran, Scarlett, Christopher J., Lock, Richard B., Liu, Tao, Norris, Murray D., Liu, Bing, Haber, Michelle, Tee, Andrew E., Carrier, Alice, Biankin, Aandrew V., London, Wendy B., Marshall, Glenn M.